New publication “Cost-effectiveness of treatment and care of patients with gastrointestinal inflammatory diseases: a systematic review”

Betthera team successfully published systematic review of the Cost-Effectiveness of Treatment and care of patients with gastrointestinal inflammatory diseases, published under the project IN ARMOR.

We systematically reviewed and synthesised the cost-effectiveness evidence for biologic versus non-biologic treatments in inflammatory bowel disease (IBD) – Crohn’s disease and ulcerative colitis – analysing 18 studies published between 2013 and 2024 from Europe, North America and Asia.

Key findings:
– Biologic therapies consistently deliver superior health outcomes (QALYs ranging 2.23–18.12) compared to conventional treatment, despite higher direct costs.
– In most evaluations, biologics are cost-effective – higher acquisition costs are offset by significant health gains.
– For Crohn’s disease, infliximab showed the most favourable cost-effectiveness profile across multiple settings. For ulcerative colitis, conclusions were more heterogeneous and context-dependent.
– Surgical colectomy, where clinically appropriate in UC, emerged as the most cost-effective option overall.

This research was supported by the IN-ARMOR project (No. 101080889), funded by the European Union, which focuses on therapeutic epigenetic enhancement of innate immunity to combat antimicrobial resistance.

You can find the fulltext of publication there.